{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:30:21Z","timestamp":1792791021399,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Emerging Fields Initiative Cell Cycle in Disease and Regeneration (CYDER) of the Friedrich-Alexander University Erlangen-N\u00fcrnberg","id":[{"id":"https:\/\/ror.org\/00f7hpc57","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28984-6","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:59:09Z","timestamp":1767023949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The AKT-p21 phosphorylation signaling axis confers poor prognosis and dacarbazine resistance in melanoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Gabriela Nana","family":"Colaneri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Cristina Biz","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e1tylas","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora Kristina","family":"Alves-Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Taveira","family":"da Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Marcelino","family":"Meliso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Santana","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Sessa","family":"Stilhano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ostalecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Schneider-Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Galvonas","family":"Jasiulionis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"28984_CR1","first-page":"9","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9\u201329 (2014).","journal-title":"CA Cancer J. Clin."},{"key":"28984_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 158, 495 (2022).","journal-title":"JAMA Dermatol."},{"key":"28984_CR3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1755-148X.2010.00773.x","volume":"23","author":"T Terzian","year":"2010","unstructured":"Terzian, T. et al. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell. Melanoma Res. 23, 781\u2013794 (2010).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"28984_CR4","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas, M. S. & Lowe, S. W. Apoptosis and melanoma chemoresistance. Oncogene 22, 3138\u20133151 (2003).","journal-title":"Oncogene"},{"key":"28984_CR5","doi-asserted-by":"crossref","unstructured":"Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29(5), 946\u2013960 (2022).","DOI":"10.1038\/s41418-022-00988-z"},{"key":"28984_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 9, 400\u2013414 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"28984_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.6000\/1929-2279.2012.01.02.5","volume":"1","author":"MT Piccolo","year":"2012","unstructured":"Piccolo, M. T. & Crispi, S. The dual role played by p21 May influence the apoptotic or Anti-Apoptotic fate in cancer. J. Can. Res. Updates. 1, 189\u2013202 (2012).","journal-title":"J. Can. Res. Updates"},{"key":"28984_CR8","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1038\/sj.onc.1206409","volume":"22","author":"C H\u00e9liez","year":"2003","unstructured":"H\u00e9liez, C., Baricault, L., Barboule, N. & Valette, A. Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells. Oncogene 22, 3260\u20133268 (2003).","journal-title":"Oncogene"},{"key":"28984_CR9","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1016\/j.febslet.2012.07.063","volume":"586","author":"AJ Vincent","year":"2012","unstructured":"Vincent, A. J. et al. Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance. FEBS Lett. 586, 3429\u20133434 (2012).","journal-title":"FEBS Lett."},{"key":"28984_CR10","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1002\/ijc.23052","volume":"121","author":"C Quirin","year":"2007","unstructured":"Quirin, C., Mainka, A., Hesse, A. & Nettelbeck, D. M. Combining adenoviral Oncolysis with Temozolomide improves cell killing of melanoma cells. Int. J. Cancer. 121, 2801\u20132807 (2007).","journal-title":"Int. J. Cancer"},{"key":"28984_CR11","doi-asserted-by":"crossref","unstructured":"Xiong, W. et al. Dacarbazine-Loaded targeted polymeric nanoparticles for enhancing malignant melanoma therapy. Front Bioeng. Biotechnol 10, (2022).","DOI":"10.3389\/fbioe.2022.847901"},{"key":"28984_CR12","doi-asserted-by":"publisher","first-page":"734","DOI":"10.5604\/17322693.966832","volume":"65","author":"K Koprowska","year":"2011","unstructured":"Koprowska, K. & Czyz, M. Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities]. Postepy Hig Med. Dosw (Online). 65, 734\u2013751 (2011).","journal-title":"Postepy Hig Med. Dosw (Online)"},{"key":"28984_CR13","doi-asserted-by":"crossref","unstructured":"Niezgoda, A., Niezgoda, P. & Czajkowski, R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed. Res. Int. 2015, (2015).","DOI":"10.1155\/2015\/851387"},{"key":"28984_CR14","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.18632\/oncotarget.1892","volume":"5","author":"E Shtivelman","year":"2014","unstructured":"Shtivelman, E. et al. Pathways and therapeutic targets in melanoma. Oncotarget 5, 1701\u20131752 (2014).","journal-title":"Oncotarget"},{"key":"28984_CR15","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2004.11.070","volume":"22","author":"DC Lev","year":"2004","unstructured":"Lev, D. C. et al. Exposure of melanoma cells to Dacarbazine results in enhanced tumor growth and metastasis in vivo. J. Clin. Oncol. 22, 2092\u20132100 (2004).","journal-title":"J. Clin. Oncol."},{"key":"28984_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.4161\/epi.6.4.14917","volume":"6","author":"F Molognoni","year":"2011","unstructured":"Molognoni, F. et al. Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics 6, 450\u2013464 (2011).","journal-title":"Epigenetics"},{"key":"28984_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1593\/neo.05781","volume":"8","author":"SM Oba-Shinjo","year":"2006","unstructured":"Oba-Shinjo, S. M. et al. Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 8, 231\u2013241 (2006).","journal-title":"Neoplasia"},{"key":"28984_CR18","doi-asserted-by":"publisher","unstructured":"Damsky, W. E., Theodosakis, N. & Bosenberg, M. Melanoma metastasis: New concepts and evolving paradigms. Oncogene 33, 2413\u20132422. https:\/\/doi.org\/10.1038\/onc.2013.194 (2014).","DOI":"10.1038\/onc.2013.194"},{"key":"28984_CR19","first-page":"81","volume":"21","author":"BCB Tonin","year":"2024","unstructured":"Tonin, B. C. B., Castro-Silva, C., de Slack, S., Jasiulionis, M. G. & F. J. & LncRNAs in melanoma phenotypic plasticity: Emerging targets for promising therapies. RNA Biol. 21, 81\u201393 (2024).","journal-title":"RNA Biol."},{"key":"28984_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. K. E. G. G. Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"28984_CR21","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: Biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"28984_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"28984_CR23","doi-asserted-by":"crossref","unstructured":"Guo, W., Wang, H. & Li, C. Signal pathways of melanoma and targeted therapy. Signal Transduction and Targeted Therapy 6, 1\u201339 (2021). (2021).","DOI":"10.1038\/s41392-021-00827-6"},{"key":"28984_CR24","doi-asserted-by":"crossref","unstructured":"Toricelli, M. et al. Timp1 promotes cell survival by activating the PDK1 signaling pathway in melanoma. Cancers (Basel) 9, (2017).","DOI":"10.3390\/cancers9040037"},{"key":"28984_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer. 9, 400 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"28984_CR26","doi-asserted-by":"publisher","first-page":"102238","DOI":"10.1016\/j.ctrv.2021.102238","volume":"99","author":"T Randic","year":"2021","unstructured":"Randic, T., Kozar, I., Margue, C., Utikal, J. & Kreis, S. NRAS mutant melanoma: Towards better therapies. Cancer Treat. Rev. 99, 102238 (2021).","journal-title":"Cancer Treat. Rev."},{"key":"28984_CR27","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.3390\/ijms25147946","volume":"25","author":"AB Boz Er","year":"2024","unstructured":"Boz Er, A. B., Sheldrake, H. M. & Sutherland, M. Overcoming Vemurafenib resistance in metastatic melanoma: targeting integrins to improve treatment efficacy. Int. J. Mol. Sci. 2024. 25, 7946 (2024).","journal-title":"Int. J. Mol. Sci. 2024"},{"key":"28984_CR28","doi-asserted-by":"crossref","unstructured":"Cicenas, J. et al. TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers (Basel) 9, (2017).","DOI":"10.3390\/cancers9050042"},{"key":"28984_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1600-0560.1997.tb00790.x","volume":"24","author":"MJ Trotter","year":"1997","unstructured":"Trotter, M. J., Tang, L. & Tron, V. A. Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1\/CIP1) in human cutaneous malignant melanoma. J. Cutan. Pathol. 24, 265\u2013271 (1997).","journal-title":"J. Cutan. Pathol."},{"key":"28984_CR30","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1046\/j.1523-1747.1999.00812.x","volume":"113","author":"ES Bales","year":"1999","unstructured":"Bales, E. S. et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J. Invest. Dermatol. 113, 1039\u20131046 (1999).","journal-title":"J. Invest. Dermatol."},{"key":"28984_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.CAN-21-0993","volume":"82","author":"A Tubita","year":"2021","unstructured":"Tubita, A. et al. Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21. Cancer Res. 82, 447 (2021).","journal-title":"Cancer Res."},{"key":"28984_CR32","doi-asserted-by":"crossref","unstructured":"Shi, S. et al. Identification of key regulators responsible for dysregulated networks in osteoarthritis by large-scale expression analysis. J Orthop. Surg. Res 16, (2021).","DOI":"10.1186\/s13018-021-02402-9"},{"key":"28984_CR33","doi-asserted-by":"crossref","unstructured":"Ma, C. & Xie, L. Prognostic model development and clinical correlation of eight key genes in skin cutaneous melanoma. Heliyon 10, (2024).","DOI":"10.1016\/j.heliyon.2024.e33930"},{"key":"28984_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/pcmr.12060","volume":"26","author":"AD Mackenzie Ross","year":"2013","unstructured":"Mackenzie Ross, A. D. et al. Senescence evasion in melanoma progression: Uncoupling of DNA-damage signaling from p53 activation and p21 expression. Pigment Cell. Melanoma Res. 26, 226\u2013235 (2013).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"28984_CR35","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1755-148X.2010.00670.x","volume":"23","author":"B \u0160est\u00e1kov\u00e1","year":"2010","unstructured":"\u0160est\u00e1kov\u00e1, B., Ondru\u0161ov\u00e1, L. & Vachtenheim, J. Cell cycle inhibitor p21\/ WAF1\/ CIP1 as a cofactor of MITF expression in melanoma cells. Pigment Cell. Melanoma Res. 23, 238\u2013251 (2010).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"28984_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00000372-199806000-00006","volume":"20","author":"LE Sparrow","year":"1998","unstructured":"Sparrow, L. E., Eldon, M. J., English, D. R. & Heenan, P. J. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am. J. Dermatopathol. 20, 255\u2013261 (1998).","journal-title":"Am. J. Dermatopathol."},{"key":"28984_CR37","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/sj.onc.1201897","volume":"16","author":"RYC Poon","year":"1998","unstructured":"Poon, R. Y. C. & Hunter, T. Expression of a novel form of p21Cip1\/Waf1 in UV-irradiated and transformed cells. Oncogene 16, 1333\u20131343 (1998).","journal-title":"Oncogene"},{"key":"28984_CR38","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/sj.bjc.6600126","volume":"86","author":"G P\u00e9rez-Tenorio","year":"2002","unstructured":"P\u00e9rez-Tenorio, G. et al. Activation of AKT\/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer. 86, 540\u2013545 (2002).","journal-title":"Br. J. Cancer"},{"key":"28984_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/35060032","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou, B. P. et al. Cytoplasmic localization of p21Cip1\/WAF1 by Akt-induced phosphorylation in HER-2\/neu-overexpressing cells. Nat. Cell. Biol. 3, 245\u2013252 (2001).","journal-title":"Nat. Cell. Biol."},{"key":"28984_CR40","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho, J. H. et al. AKT1 activation promotes development of melanoma metastases. Cell. Rep. 13, 898\u2013905 (2015).","journal-title":"Cell. Rep."},{"key":"28984_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ccr.2005.12.026","volume":"9","author":"M Malumbres","year":"2006","unstructured":"Malumbres, M. & Barbacid, M. Is Cyclin D1-CDK4 kinase a Bona Fide cancer target? Cancer Cell. 9, 2\u20134 (2006).","journal-title":"Cancer Cell."},{"key":"28984_CR42","doi-asserted-by":"publisher","first-page":"11352","DOI":"10.1074\/jbc.M109062200","volume":"277","author":"Y Li","year":"2002","unstructured":"Li, Y., Dowbenko, D. & Lasky, L. A. AKT\/PKB phosphorylation of p21Cip\/WAF1 enhances protein stability of p21Cip\/WAF1 and promotes cell survival. J. Biol. Chem. 277, 11352\u201311361 (2002).","journal-title":"J. Biol. Chem."},{"key":"28984_CR43","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1158\/1078-0432.CCR-03-0527","volume":"10","author":"W Xia","year":"2004","unstructured":"Xia, W. et al. Phosphorylation\/cytoplasmic localization of p21Cip1\/WAF1 is associated with HER2\/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 10, 3815\u20133824 (2004).","journal-title":"Clin. Cancer Res."},{"key":"28984_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS El-Deiry","year":"1993","unstructured":"El-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817\u2013825 (1993).","journal-title":"Cell"},{"key":"28984_CR45","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4161\/cc.1.6.262","volume":"1","author":"MV Blagosklonny","year":"2002","unstructured":"Blagosklonny, M. V. Are p27 and p21 cytoplasmic oncoproteins? Cell. Cycle 1, 391\u2013393 (2002).","journal-title":"Cell. Cycle"},{"key":"28984_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1006\/excr.2002.5548","volume":"277","author":"M Rahmani","year":"2002","unstructured":"Rahmani, M., Dai, Y. & Grant, S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-\u03b1-mediated process. Exp. Cell. Res. 277, 31\u201347 (2002).","journal-title":"Exp. Cell. Res."},{"key":"28984_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbrc.2010.10.126","volume":"403","author":"X Cheng","year":"2010","unstructured":"Cheng, X. et al. Activation of p21(CIP1\/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem. Biophys. Res. Commun. 403, 103\u2013107 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"28984_CR48","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1074\/jbc.M010840200","volume":"276","author":"RA Campbell","year":"2001","unstructured":"Campbell, R. A. et al. Phosphatidylinositol 3-kinase\/AKT-mediated activation of Estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817\u20139824 (2001).","journal-title":"J. Biol. Chem."},{"key":"28984_CR49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.stem.2009.01.007","volume":"4","author":"AM Bleau","year":"2009","unstructured":"Bleau, A. M. et al. PTEN\/PI3K\/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell. Stem Cell. 4, 226\u2013235 (2009).","journal-title":"Cell. Stem Cell."},{"key":"28984_CR50","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/jid.2008.379","volume":"129","author":"T Sinnberg","year":"2009","unstructured":"Sinnberg, T. et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and Temozolomide. J. Invest. Dermatol. 129, 1500\u20131515 (2009).","journal-title":"J. Invest. Dermatol."},{"key":"28984_CR51","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1158\/1078-0432.CCR-04-1385","volume":"11","author":"A Shah","year":"2005","unstructured":"Shah, A. et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin. Cancer Res. 11, 2930\u20132936 (2005).","journal-title":"Clin. Cancer Res."},{"key":"28984_CR52","doi-asserted-by":"crossref","unstructured":"Suzuki, A., Tsutomi, Y., Miura, M. & Akahane, K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 18(5), 1239\u20131244 (1999).","DOI":"10.1038\/sj.onc.1202409"},{"key":"28984_CR53","doi-asserted-by":"crossref","unstructured":"Suzuki, A. et al. Survivin initiates procaspase 3\/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19(10), 1346\u20131353 (2000).","DOI":"10.1038\/sj.onc.1203429"},{"key":"28984_CR54","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1093\/emboj\/18.5.1223","volume":"18","author":"M Asada","year":"1999","unstructured":"Asada, M. et al. Apoptosis inhibitory activity of cytoplasmic p21Cip1\/WAF1 in monocytic differentiation. EMBO J. 18, 1223\u20131234 (1999).","journal-title":"EMBO J."},{"key":"28984_CR55","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/cancers10100373","volume":"10","author":"A Maiuthed","year":"2018","unstructured":"Maiuthed, A. et al. Cytoplasmic p21 mediates 5-Fluorouracil resistance by inhibiting Pro-Apoptotic Chk2. Cancers (Basel). 10, 373 (2018).","journal-title":"Cancers (Basel)"},{"key":"28984_CR56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ncb974","volume":"5","author":"C Stevens","year":"2003","unstructured":"Stevens, C., Smith, L. & La Thangue, N. B. Chk2 activates E2F-1 in response to DNA damage. Nat. Cell. Biol. 5, 401\u2013409 (2003).","journal-title":"Nat. Cell. Biol."},{"key":"28984_CR57","doi-asserted-by":"publisher","unstructured":"Xia, X. et al. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. https:\/\/doi.org\/10.1186\/1471-2407-11-399 (2011).","DOI":"10.1186\/1471-2407-11-399"},{"key":"28984_CR58","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI41939","volume":"120","author":"R Koster","year":"2010","unstructured":"Koster, R. et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J. Clin. Invest. 120, 3594\u20133605 (2010).","journal-title":"J. Clin. Invest."},{"key":"28984_CR59","doi-asserted-by":"crossref","unstructured":"De Souza, C. F., Morais, A. S. & Jasiulionis, M. G. Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol. Res. Pract. 2012, 14 (2012).","DOI":"10.1155\/2012\/156068"},{"key":"28984_CR60","first-page":"41","volume":"13","author":"NT Ihle","year":"2010","unstructured":"Ihle, N. T. & Powis, G. The biological effects of isoform-specific PI3-kinase Inhibition. Curr. Opin. Drug Discov Devel. 13, 41\u201349 (2010).","journal-title":"Curr. Opin. Drug Discov Devel"},{"key":"28984_CR61","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/ijc.2910390324","volume":"39","author":"DC Bennett","year":"1987","unstructured":"Bennett, D. C., Cooper, P. J. & Hart, I. R. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer. 39, 414\u2013418 (1987).","journal-title":"Int. J. Cancer"},{"key":"28984_CR62","doi-asserted-by":"crossref","unstructured":"Souza, C. F. et al. Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. PLoS One 7, (2012).","DOI":"10.1371\/journal.pone.0044800"},{"key":"28984_CR63","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45, W98 (2017).","journal-title":"Nucleic Acids Res."},{"key":"28984_CR64","doi-asserted-by":"crossref","unstructured":"Borcherding, N., Bormann, N. L., Voigt, A. P., Zhang, W. & TRGAted A web tool for survival analysis using protein data in the cancer genome atlas. F1000Res 7, (2018).","DOI":"10.12688\/f1000research.15789.2"},{"key":"28984_CR65","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1158\/0008-5472.CAN-17-0369","volume":"77","author":"J Li","year":"2017","unstructured":"Li, J. et al. Explore, Visualize, and analyze functional cancer proteomic data using the cancer proteome atlas. Cancer Res. 77, e51\u2013e54 (2017).","journal-title":"Cancer Res."},{"issue":"984\u20136","key":"28984_CR66","first-page":"980","volume":"7","author":"AD Miller","year":"1989","unstructured":"Miller, A. D. & Rosman, G. J. Improved retroviral vectors for gene transfer and expression. Biotechniques 7(984\u20136), 980\u2013982 (1989).","journal-title":"Biotechniques"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28984-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28984-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28984-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:03:14Z","timestamp":1777125794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28984-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28984"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28984-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7077835\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study involved the analysis of previously collected human tissue samples. All samples were de-identified and obtained in compliance with institutional ethical guidelines. The use of these samples for research purposes was approved by the Ethik-Kommission of the FAU Erlangen-N\u00fcrnberg. No new samples were collected specifically for this study, and no animal experiments were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"44864"}}